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Neutropenia is uncommon but a very challenging problem in medicine. It remains a well-known risk factor for the development of 
infection while conversely neutropenia can be caused by infection or its treatment. The issue is discussed in the paper with respect to 
different patient populations, medical intervention, and life situations.
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Introduction
Neutropenia is defined as a decrease in circulating neutrophils 
(absolute neutrophil count), in persons and the normal level of adults 
is <1.5 G/L, and is classified as mild when level is 1–1.5, moderate 
when 0.5–1.0, and severe when <0.5. Differential diagnosis of 
neutropenia is a difficult interdisciplinary problem with congenital and 
acquired causes along with the impact of comorbidities, infections, 
and medications. Neutropenia coexisting with thrombocytopenia and 
anemia is a manifestation of bone marrow damage (aplastic anemia, 
myelodysplastic syndrome, and chemoradiotherapy), bone marrow 
infiltration (acute leukemia) or deficiency (megaloblastic anemia). 
Isolated neutropenia is a common hematological finding, usually 
based on a timeframe of 3 months and may be divided into acute 
and chronic forms. It can be diagnosed as an inherited/congenital 
disorder or an acquired condition. Most inherited neutropenia cases 
are diagnosed before the age of 10 years. Among the inherited 
causes of neutropenia, including benign ethnic neutropenia (mainly 
in individuals of African descent), familiar neutropenia, and other 
congenital neutropenia with or without somatic findings such as 
premature graying of hair, cardiac or urogenital abnormalities 
(G6PC3 mutation), and skeletal abnormalities (Shwachman-Diamond 
syndrome), the most common is cyclic congenital neutropenia. It is 
often caused by an ELANE mutation which should be considered in 
patients with episodic, recurrent aphthous ulcers and confirmed by 
performing a complete blood count at least twice a week up to six 
weeks. Other genetic causes of neutropenia include WAS, SBDS, 
and HAX1. On the other hand, the presentation of chronic idiopathic 
neutropenia or idiopathic neutropenia may be asymptomatic or may 
lead to recurrent infections with fever, gingivitis or aphthous ulcers. 
Neutropenia is often found in the course of rheumatologic disorders 
such as rheumatoid arthritis, including Felty syndrome, systemic 
lupus erythematosus, and Sjögren syndrome, and should be excluded 
in differential diagnosis [1, 2]. Above all, an underappreciated cause 
of neutropenia is infections, thus neutropenia can be a complication 
of viral, bacterial, and parasitic infections. There are several 
mechanisms leading to neutropenia in the course of infections 
including impaired proliferation and differentiation in the bone marrow, 
incorrect distribution of circulating granulocytes and their adhesion 
to the vascular endothelium, excessive sequestration of circulating 
granulocytes in the spleen and/or their destruction in the course of 
immune processes, nutritional deficiencies or the pharmacotherapy 
used. Neutropenia in the course of infections is most often transient, 
lasts <3 months and is usually unnoticeable. This is often the case 
with the course of viral infections and, less often, it is associated 
with acute bacterial infections (sepsis) or less severe bacterial and 
protozoal infections [3, 4].
Infectious complications during neutropenia
Infections during neutropenia are life threatening. The risk 
of their occurrence increases in the severe form cases with 
a neutrophil count below 0.5 G/L lasting more than 7 days. 
Such condition is usually seen in patients undergoing intensive 
antineoplastic treatment (e.g., chemotherapy for acute myeloid 
leukemia or treatment with hematopoietic cell transplantation) and 
accompanied by thrombocytopenia and anemia (pancytopenia). 
The Multinational Association for Supportive Care in Cancer 
(MASCC) scale, taking into account clinical symptoms and the 
presence of comorbidities, allows for the identification of patients with 
high (number of points <21) and low risks of infectious complications 
(Tab. I).
In the course of neutropenia, bacterial infections are the most common, 
less frequently fungal and viral infections are seen. Bacteria are 
responsible for blood stream infections mainly, occurring in 13–60% 
of patients with mortality reaching 12–42%. About 50% of bacterial 
infections during neutropenia are caused by Gram-positive ones, 
especially methicillin-resistant coagulase-negative staphylococci, 
but also by Streptococcus sp. An increasing threat in recent 
years is the increase of infections caused by resistant pathogens: 
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vancomycin-resistant enterococci (VRE) and staphylococci 
(vancomycin-intermediate Staphylococcus aureus [VISA]; 
hetero-resistant Staphylococcus aureus [hVISA]). Infections with 
Gram-negative bacteria, especially those of resistant pathogens, 
are among the most serious complications associated with 
high mortality rate of around 50%. Pseudomonas aeruginosa, 
Escherichia coli, Klebsiella sp., and Acinetobacter sp. are the most 
common causes of infections.
Infections during neutropenia spread quickly, posing a direct 
threat to life, therefore the immediate implementation of empirical 
antibiotic therapy is obligatory, without waiting for identification of 
the pathogen and its susceptibility determination. The principle 
of treatment is the intravenous administration of broad-spectrum 
antibiotics against both Gram-positive and Gram-negative 
bacteria, and its modification depending on response to therapy, 
clinical condition, and microbiological test results. The choice 
of empirical treatment should be based on the frequency and 
sensitivity of the pathogens present in a given ward, as well as 
the experience of the center. Currently, two empirical strategies 
are employed: escalation therapy, consisting of modification 
depending on the clinical condition and results of microbiological 
tests, or de-escalation, based on application from the beginning 
of combination antibiotic therapy including antibiotics against 
resistant pathogens. In patients with a confirmed bacterial 
infection, especially resistant pathogens, targeted and narrowed 
therapy should be implemented. It is emphasized that the 
targeted therapy should be based on the bacterial sensitivity in 
vitro, the confirmed efficacy of the antibiotic in the treatment of 
infections caused by a given pathogen, the pharmacokinetic and 
pharmacodynamic data, and also individual analysis of the risks 
and benefits of the treatment used [5, 6].
Persistent or recurrent neutropenic fever despite the administration of 
broad spectrum of antibiotics may suggest invasive fungal infection. 
The most common fungal pathogens responsible for neutropenic 
infection is Aspergillus sp. followed by Mucorales. Candida sp. 
infections, which are currently rare, diagnosed in approximately 5% 
of patients as a blood stream infection, however, mortality in their 
course may exceed 20%. The strategy of antifungal therapy during 
neutropenia includes empirical therapy, pre-emptive treatment, 
and treatment for confirmed mycosis defined and described by 
European Conference on Infections in Leukemia (ECIL) [7, 8, 9].
Infection-induced neutropenia
Bacterial infections as a cause of neutropenia
Although leukocytosis is usually observed due to bacterial infections 
with an increase in the number of bands (shift of maturation to the 
left), in some bacterial infections symptoms such as typhoid fever, 
bacterial dysentery, brucellosis, tularemia or tuberculosis, and 
a decrease in the number of granulocytes are observed [10, 11].
Sustained fever with abdominal symptoms after returning from 
endemic areas may indicate typhoid fever. Typhoid fever is a disease 
among tropical diseases responsible for up to 20–30% of admissions 
with leukopenia and neutropenia to the intensive care units and 
other complications in Africa, Asia, and South Africa [12, 13, 14]. 
Bone marrow evaluation often shows granulocytic hyperplasia with 
hemaphagocytosis, whose severity correlates with peripheral blood 
cytopenia followed by hemaphagocytosis [15]. The pathomechanism 
of neutropenia in typhoid fever is complex and includes the 
presence of endotoxins, cytokines including tumor necrosis factor 
(TNF), interleukin 6 (IL-6), and interferon γ (IFN-γ) contributing to 
increased hemophagocytosis. All these inflammatory mediators 
lead to upregulation of endothelial adhesion molecules and a shift 
of peripheral granulocytes to endothelium [16, 17]. Cases of typhoid 
fever imported because of travelers from India and Nepal are also 
published in Polish literature [18].
In the course of shigella enteritis, abnormalities in the granulopoeitic 
system, ranging from leukopenia to leukocytosis, are also observed, 
with a shift to less mature band forms in the peripheral blood. The 
mechanism of these disorders is unknown. A shigella infection 
can lead to serious systemic complications, including septicemia, 
hemolytic uremic syndrome or a leukemoid reaction. The occurrence 
of neutropenia, in both adults and children, is an unfavorable 
prognostic factor [19].
The incidence of neutropenia will be up to 30% for adults and children 
with brucellosis, and almost 20% of patients have pancytopenia 
[20, 21]. The spleen size is related to the severity of hemophagocytosis 
and the development of non-serous granulomas in the bone marrow 
[22]. In an assessment of the leukocyte immunophenotype in patients 
with brucellosis, shifts to the left in the granulocytic lineage and 
disturbances in the activation of T and B lymphocytes and monocytes 
are found [23].
Table I. MASCC scale
Characteristic Weight
Burden of febrile neutropenia symptoms






No hypotension (systolic BP > 90 mmHg) 5
No chronic obstructive pulmonary disease 4




High risk for poor outcome: <21 points
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Neutropenia is occasionally observed in the course of tularemia, 
zoonosis shows the involvement of ulcer-glandular lymph node and 
sometimes pneumonia. In rare situations, it can be life-threatening 
in immunocompromised patients, including patients after allogeneic 
hematopoietic stem cell transplantation [24]. The effect of these 
bacteria on neutrophil and macrophage functions is well known. It has 
been shown that these bacteria can change their overall response 
to antigens, induce disorders in neutrophil recruitment mechanisms, 
disorders in opsonization and phagocytosis and cause inhibition of 
neutrophil defense mechanisms [25].
Neutropenia is observed in the most of severe cases of disseminated 
miliary tuberculosis with pancytopenia and is estimated to be around 
5% of all patients. Furthermore, it may lead to lymphopenia in almost 
87% of cases, leukopenia in approximately 15% of patients, and 
thrombocytopenia in 23% of cases [26, 27].
Rickettsia infections can also lead to neutropenia including 
rickettsialpox, human granulocytic anaplasmosis, and Rocky 
Mountain spotted fever [28]. Rickettsiae occur mainly in Africa, 
the Mediterranean, and southern Europe, as well as in the United 
States and Canada [29, 30, 31]. One of the rickettsia infections, 
Anaplasma phagocytophilum, often diagnosed in Poland and other 
European countries, may lead to leukopenia with neutropenia, 
thrombocytopenia, and increased hepatic transaminase activities at 
early presentation of the disease [32–36].
Parasitic infections as a cause of neutropenia
The occurrence of neutropenia is mainly observed in the course of 
two parasitic infections, malaria and leishmaniasis. Both diseases 
occur in endemic regions. Leishmania flagellate infections occur in 
the Mediterranean, East Africa, and South America, while malaria 
is endemic to Africa, India, and Southeast Asia. In Poland, these 
diseases occur occasionally, usually, imported from endemic regions, 
but diagnosing them is a serious problem. The most dangerous form 
of the disease is visceral leishmaniasis caused mainly by Leishmania 
donovani, which leads to fever, hepatosplenomegaly, and neutropenia 
in the course of pancytopenia. Large studies have shown that the 
incidence of leukopenia reaches 75% of visceral leishmaniasis 
cases. It is believed that hypersplenism is the main cause of its 
development [37, 38]. The presence of myeloid hyperplasia, an 
increased number of lymphocytes, plasma cells and megakaryocytes, 
hemophagocytosis (phagocytosis of erythrocytes, leukocytes, and 
platelets occur in 46% of cases), ineffective erythropoiesis, and 
granulomas can be found in the course of visceral leishmaniasis. The 
severity of the hematological changes depends on the duration of the 
disease and the size of the spleen, not on the number of parasitized 
mononuclear cells [38]. Severe neutropenia in celiac leishmaniasis is 
prognostically unfavorable factor [39].
Malaria is a tropical disease caused by a protozoan of the genus 
Plasmodium (out of 120 Plasmodium sp., the six species of malaria 
parasites including Plasmodium falciparum, Plasmodium vivax, 
Plasmodium ovale wallickeri, Plasmodium ovale curtisi, Plasmodium 
malariae, and Plasmodium knowlesi are pathogenic for humans), 
transmitted by a vector – Anopheles mosquito, and the disease 
occurs in 91 countries around the world [40, 41, 42]. The incidence of 
neutropenia at diagnosis is seen in 7% of malaria cases caused by 
Plasmodium falciparum and increases in the first 7 days of treatment. 
In one-third of all neutropenia cases, the number of granulocytes 
falls below 0.5 G/L. The risk of neutropenia increases with the 
observation time, along with higher levels of baseline parasitemia, 
althoguh it is independent of the final treatment result and is lower 
in the elderly and during combination therapy with artemisinin 
[43]. The pathomechanism of neutropenia in the course of malaria 
is complex, including an increase in the number of sporozoites in 
peripheral blood, disturbances in the distribution of granulocytes with 
its marginalization, and a decrease in both the number of mature 
granulocytes and myeloid reserve by premature release of immature 
forms from the bone marrow [44].
Viral infections as a cause of neutropenia
In the majority of cases, in children and young adults, mild to moderate 
neutropenia is thought to be due to transient myelosuppression 
caused by various viral infections [45]. Neutropenia is observed in 
patients infected with Herpes viruses (EBV, CMV, HHV6, and HSV), 
respiratory tract viruses (RSV, influenza A and B, and parainfluenza), 
and hepatitis viruses, as well as other viral exanthematous diseases, 
including chickenpox, rubella, and measles. Neutropenia often 
occurs during the first few days of the viral disease and lasts for 
3–8 days [45].
The Epstein–Barr virus (EBV) infection is common and affects 
more than 80% of the world’s population [31]. It is most common 
in children, while in young adults it may cause an acute infection 
with fever, pharyngitis, lymphadenopathy, and splenomegaly. The 
EBV virus infects B lymphocytes, and in a peripheral blood smear 
lymphocytosis with atypical lymphocytes is detected along with 
antibodies to erythrocytes, neutrophils, and EBV [46, 47]. The 
presence of anti-neutrophil antibodies and their transient aggregation 
leads to neutropenia [46, 48]. Rare hematological complications of 
acute infection include hemolytic anemia and thrombocytopenia, 
which occur in <1% of cases [49]. After infection, the virus remains 
in the body in a persistent form. EBV has been shown to have 
oncogenic potential, especially in endemic forms of Burkitt’s 
lymphoma, it also plays a role in the pathogenesis of Hodgkin’s 
lymphoma, epithelial and gastric cancers, and the development of 
post-transplant lymphoproliferative disease (PTLD) in both organ 
transplant recipients and hematopoietic cell recipients (HCT) [49].
Cytomegalovirus (CMV) infection is also a common infection, it 
can cause fever, sore throat, lymphadenopathy, splenomegaly, and 
myalgia in adolescents and young adults. Transient mild neutropenia 
and thrombocytopenia may occur in its course [50]. After infection, the 
virus remains in the body in a persistent form. CMV infection is one of 
the main causes of morbidity and mortality in immunocompromised 
individuals, including AIDS patients and HCT recipients and after solid 
organ transplantation. In this group of patients, the most common 
hematological disorders include neutropenia and thrombocytopenia, 
but the infection may lead to secondary transplant rejection [50]. The 
average frequency of CMV reactivation after HCT was estimated to 
be, 37% after allogeneic transplantation, 30% in solid organ transplant 
recipients, 20% during active replication in HIV infected patients, and 
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3.3% during antiretroviral therapy. The highest risk of CMV infection 
and CMV disease was demonstrated in seropositive HCT recipients 
[51]. Neutropenia also increases with ganciclovir, used to treat CMV 
infections and diseases.
Hepatitis A rarely leads to transient neutropenia, most often occurs 
in the second week of infection, but in some cases, agranulocytosis 
occurs [52, 53]. However, mild to moderate neutropenia is often 
diagnosed in the course of chronic hepatitis C (HCV) [54]. The 
development of neutropenia occurs as a result of the inhibitory 
effect of the virus on myelopoiesis, hypersplenism, and autoimmune 
processes [54, 55]. Neutropenia can also occur in patients with 
chronic hepatitis B, usually its severity is related with the development 
of liver cirrhosis and hypersplenism [56, 57].
Primary infection with herpes virus-6, which causes sudden erythema 
in children (also called three-day fever), is especially dangerous in 
recipients of solid organs and hematopoietic cells and can lead to 
neutropenia, often during the course of severe pancytopenia [58, 59]. 
The infection is often accompanied by skin lesions such as roseola 
infantum and neurological disorders.
Leukopenia with mild neutropenia and lymphopenia is commonly 
found in the course of viral rash diseases such as measles, 
rubella, and chickenpox. In the course of measles, leukocytosis is 
usually observed during the incubation period, followed by a sharp 
decrease in the number of granulocytes with the lowest value during 
the time of skin lesions [60, 61]. Impaired neutrophil chemotaxis 
and phagocytosis are also observed, which leads to secondary 
impairment of immunity [62, 63, 64]. The measles vaccine contains 
a live, attenuated measles virus which may cause transient mild 
neutropenia between days 3 and 16 [65].
In the course of rubella, neutropenia occurs in about 50% of cases 
and disappears slowly within six weeks [66]. In isolated cases, 
severe neutropenia is observed in chickenpox, which usually causes 
leukocytosis and neutrophilia [67].
Neutropenia often occurs in patients with human immunodeficiency 
virus (HIV) infection. The causes of neutropenia in the course of 
this infection are complex and include the toxic effect of the virus on 
hematopoiesis, the effect of infections secondary to HIV infection, and 
the use of myelotoxic agents in its treatment. Increased incidence and 
the severity of neutropenia are particularly marked in the advanced 
stages of HIV. In addition, reduced neutrophil counts in the blood 
are closely related to CD4+ cell loss and inversely related with HIV 
viremia [68, 69, 70]. Opportunistic infections in HIV that can induce 
or exacerbate myelosuppression and neutropenia are numerous and 
include Mycobacterium avium Complex, Mycobacterium tuberculosis, 
Cryptococcus neoformans, Candida albicans, Pneumocystis jiroveci, 
Toxoplasma gondii, and infection with hepatitis B virus infection. 
Some of these infections show increased destruction of granulocytes 
in the peripheral blood or their sequestration in the enlarged spleen 
[69].
Another example of neutropenia, which is seen in travelers especially 
in endemic areas and considered in differential diagnosis of fever, 
is acute Dengue virus infection (benign neutropenia occurs in 76–
100% of cases) [71–74]. Neutropenia may also occur in the course of 
yellow fever and other viral infections [75–78]. It is believed that the 
main cause of leukopenia or neutropenia is the direct effect on the 
bone marrow by viruses.
Antibiotic-induced neutropenia
The occurrence of neutropenia may not only be caused by infections, 
but may also be induced by the anti-infective treatment used. The 
incidence of treatment-induced neutropenia is estimated around 4 
cases per 10,000 hospitalized patients [79]. Among the undesirable 
effects, regardless of the route of administration (oral or parenteral), 
the incidence of neutropenia is 6% [80]. One of the most common 
causes of neutropenia is the use of antibiotic therapy, particularly beta-
lactams, sulfamethoxazole with trimethoprim and vancomycin [81]. With 
antibiotic-induced neutropenia immediate discontinuation of treatment is 
indicated. In most cases, neutropenia resolves spontaneously.
Infection-induced neutropenia in children
It is believed that in both transient and chronic neutropenia in children, 
it is possible to identify infectious causes in more than 50% of cases 
[82, 83]. In 85% of children, neutropenia is diagnosed accidently [84] 
and resolves spontaneously. Acute transient neutropenia most often 
occurs after viral infections. It can start a few days before the infection 
starts and usually lasts until the end of the viremia. Viral infections, 
including chickenpox, measles, rubella, hepatitis A and B, influenza, 
cytomegalovirus, EBV, parvovirus B19, adenovirus, and coxsackie 
lead to neutropenia, resulting in reduced production and increased 
destruction of granulocytes. Neutropenia in children can also be 
observed due to bacterial infections, including Staphylococcus aureus, 
and in the course of brucellosis, rickettsiosis, and tuberculosis [85].
Hemophagocytic syndrome secondary to 
infections
Hemophagocytic lymphohistiocytosis (HLH) or macrophage 
activation syndrome (MAS) secondary to infections should be 
considered when interpreting neutropenia reports/results in the 
course of some infections. Cytopenia and splenomegaly are the 
result of macrophage activation in response to many stimuli including 
numerous viral, bacterial, parasitic, and fungal infections. It is 
believed that this reaction can be triggered by viruses, in particular 
EBV, cytomegalovirus, HIV, and H1N1 influenza virus [86, 87]. There 
are also reports indicating the role of parvovirus, herpes simplex 
virus, varicella-zoster virus, disseminated adenovirus, measles 
virus, and human herpes virus 8 [88–93]. HLH can also occur in 
infections caused by bacteria include visceral leishmaniasis, atypical/
tuberculous mycobacteria, histoplasmosis, ehrlichia, bartonella, and 
Brucella species [89]. It is believed that HLH-like syndrome can be 
triggered by SARS-CoV-2 [94, 95].
Travel-induced infections and neutropenia
A history of traveling, especially in some endemic areas of diseases, 
should be considered in differential diagnosis of neutropenia. Selected 
issues characterizing neutropenia in the course of bacterial infections 
including geographical distribution, source and transmission, along 
with recommendations for travelers are presented in table II. Travel-
related pandemic/endemic viral diseases leading to neutropenia are 
shown in table III.
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Table II. Selected issues characterized by neutropenia in the course of bacterial infections including geographical distribution, 
source, and transmission with recommendations for travelers







25–50%  Still endemic in India and 
Pakistan, Africa, Far East Asia, 
the Middle East and South 
and Central America
Salmonella bacteria are 
widely distributed in domes-
tic and wild animals. They 
are prevalent in food animals 
such as poultry, pigs, and 
cattle; and in pets, including 
cats, dogs, birds, and reptiles 
such as turtles
Ensure food is properly 
cooked and still hot when 
served.
Avoid raw milk and products 
made from raw milk. Drink 
only pasteurized or boiled 
milk. Avoid ice unless it 
is made from safe water. 
Wash hands thoroughly and 
frequently using soap, in 
particular after contact with 
pets or farm animals, or after 
having been to the toilet. 
Wash fruits and vegetables 
carefully, particularly if they 
are eaten raw. If possible, 
vegetables and fruits should 
be peeled
Shigellosis Shigella: S. dysenteriae, 




The highest for people 
traveling to Africa, followed 
by Central America, South 
America, and Asia
Shigella is transmitted 
via the fecal–oral route, 
including through direct 
person-to-person or sexual 
contact or indirectly through 
contaminated food, water, 
or fomites
No vaccines are available.
Frequent handwashing, 
strict adherence to standard 
food and water safety 
precautions and minimizing 
fecal–oral exposure during 
sexual activity
Brucellosis Brucella melitensis, 
Brucella suis, Brucella 
abortus, Brucella canis
20–30% Worldwide, in animals, most 
common in developing 
countries, South America, 
central Asia, the Mediterra-
nean and the Middle East
Primarily a disease of 
animals. Infection in people 
is acquired from cattle (Bru-
cella abortus), dogs (B. canis), 
pigs (B. suis), or sheep and 
goats (B. melitensis), usually 
by direct contact with infect-
ed animals or by consump-
tion of unpasteurized (raw) 
milk or cheese
Avoid consumption of 
unpasteurized milk and milk 
products and direct contact 
with animals, particularly 
cattle, goats, and sheep
Tularemia Francisella tularensis Rare The northern hemisphere 
– North America, Russia, 
Europe, and Japan
Primarily a disease of a wide 
variety of wild mammals 
and birds. Humans become 
infected mainly through 
the bite of arthropods, 
particularly ticks and 
mosquitoes, and through 
the skin, conjunctival sac or 
oropharyngeal mucosa, by 
direct contact with infected 
animals or animal materials 
and by ingestion of con-
taminated food or water or 
inhalation of contaminated 
dust or aerosols
The use of insect repellents, 
wearing appropriate 
clothing during a stay in 
the forest (long legs and 
sleeves), quick removal of 
ticks, avoiding consump-
tion of untreated water 
from natural water bodies, 
proper heat treatment of 
meat before consumption, 
not touching sick or dead 
animals, using gloves when 
touching rabbits, muskrats, 
prairie dogs and other 
animals, using masks in sit-
uations where there is a risk 
of inhalation of bacteria into 
the respiratory system (e.g. 







Mainly in Third World coun-
tries, in highly developed 
countries due to a decrease 
in immunity in the course 
of immunosuppressive 
treatment, addiction or HIV 
infection
Spread through the air when 
people who have active TB 
in their lungs cough, spit, 
speak, or sneeze
Tuberculosis prevention and 
control efforts rely primarily 
on the vaccination of infants 
and the detection and 
appropriate treatment of 
active cases
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Infection-induced neutropenia in transplant recipients
In the setting of HCT recipients, recurrent neutropenia is a common 
observation even after hematological reconstitution. This condition 
is usually transient and related to the viral infections described 
above: CMV, EBV, HHV-6, and Herpes simplex [96, 97, 98]. In 
specific situations, the Zika infection may also be considered [99]. 
Additionally, severe bacterial infection may cause neutropenia, 
especially in the course of septic shock. In differential diagnosis the 
formation of antibodies directed against granulocytes in autoimmune 
neutropenia after HCT should be included [96, 100]. Although 
autoimmune neutropenia most often occurs in the early post-
transplant period, cases of late-occurring neutropenia with identified 
antibodies against human neutrophil antigens (usually type 2 and 
type 1a) following upper respiratory tract viral infections are also 
reported in the literature [101].
Summary
Neutropenia remains an important interdisciplinary issue, which 
requires special attention. One should emphasize on complex causes 
of infection-induced neutropenia and risk of infections in the course 
of severe neutropenia. So for travelers or immunocompromised 
patients in these clinical situations, proper diagnosis and treatment 
of this condition help to avoid complications and may improve the 
outcomes.
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frequency Geographical distribution Source and transmission
Chikungunya 4% of hospital 
admission





>50% Africa, the Balkans, the Middle East, and 
Asia
Spreads to humans either by tick-bites, or through contact with 
viremic animal tissues
Ebola virus disease In case fatality Central Africa, near tropical rainforests, 
Guinea, Sierra Leone, and Liberia
Transmitted to people from wild animals (such as fruit bats, porcu-
pines and non-human primates) and then spreads in the human pop-
ulation through direct contact with the blood, secretions, organs or 
other bodily fluids of infected people, and with surfaces and materials 
(e.g. bedding, clothing) contaminated with these fluids
Dengue fever virus In severe cases Africa Mosquito-borne viral infection 
Colorado tick fever 
virus
Major finding The western United States Transmitted by ticks 
Yellow fever First week Tropical areas of Africa and Central and 
South America






In the subtropical zone of the Eastern 
Hemisphere, particularly in Southern 
Europe, North Africa, the Balkans, Eastern 
Mediterranean, Iraq, Iran, Pakistan, 
Afghanistan, and India
A vector-borne febrile arboviral infection caused by the bite of the 
sandfly
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